Imvotamab is under clinical development by IGM Biosciences and currently in Phase II for Non-Hodgkin Lymphoma. According to GlobalData, Phase II drugs for Non-Hodgkin Lymphoma have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Imvotamab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Imvotamab overview
Imvotamab is under development for the treatment of rituximab resistant/refractory diffuse large cell lymphoma, mantle cell lymphoma, marginal zone B-cell lymphoma, relapsed and refractory B cell non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), systemic lupus erythematosus (SLE), rheumatoid arthritis(RA) and idiopathic inflammatory myopathy (myositis). The therapeutic candidate is a bi-specific T cell engager IgM antibody targeting CD20 and CD3. It is developed based on IgM antibody technology.
IGM Biosciences overview
IGM Biosciences operates as a biotechnology company that develops novel antibodies for the treatment of cancer and other diseases. The company’s pipeline products include aplitabart an IgM antibody targeting death receptor 5 (DR5) that treats colorectal cancer; imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins for systemic lupus erythematosus, rheumatoid arthritis; and IGM-2644 targets autoimmune diseases. It utilizes IgM and IgA antibodies technology for developing its products. IGM Biosciences is headquartered in Mountain View, California, the US.
For a complete picture of Imvotamab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
